Last reviewed November 16, 2026. Educational information only, not medical advice.
BPC-157 is one of the most talked-about peptides online, and since July 2026 it has also been one of the most confusing. An FDA advisory committee voted to let pharmacies compound it, HHS then said it would not enforce against compounding pharmacies, and many people read both as approval. Neither is. This page covers what BPC-157 is, what the research actually shows, what side effects are reported and where it stands legally.
The short version
BPC-157 is a lab-made peptide with a large body of animal research and very little human research. It is not FDA approved. Since October 30, 2026, HHS has allowed licensed US compounding pharmacies to prepare it with a prescription while the FDA finishes its review. There is no established human dose.
What is BPC-157?
BPC-157 stands for Body Protection Compound-157. It is a synthetic chain of 15 amino acids, based on part of a protein first identified in human gastric juice. It was discovered by a research group in Zagreb, Croatia, in the early 1990s, and most of the published research on it still comes from that group.
Online, it is often called the “Wolverine peptide” because of claims that it speeds up healing. It is sold as a freeze-dried powder for injection, and more recently in oral forms. It has no approved medical use anywhere in the world.
What the research shows
Animal and laboratory studies
Researchers have studied BPC-157 in rats, mice and cell cultures for over 30 years. That work has looked at:
- Healing of tendons, ligaments, muscle and bone
- Protection of the stomach and intestinal lining
- Blood-vessel growth (angiogenesis) and blood flow to injured tissue
- Inflammation and nitric-oxide signaling
- Nerve recovery after injury
Many of these studies report positive results, which is why interest is so high. But animal results often fail to carry over to people. A 2025 systematic review of BPC-157 for orthopedic and sports-medicine uses screened 544 published articles and found only 36 that met its standards: 35 animal studies and one clinical study.
Human studies
The published human evidence is very small:
- Knee pain (2021): a small retrospective study of injections into the knee, with no control group, using patients’ own reports of pain relief.
- Interstitial cystitis (2024): a pilot study of 12 women with a painful bladder condition, again with no control group.
- Intravenous safety pilot (2025): a safety test in two healthy adults, which reported no abnormal lab results over the short study period.
- Phase I trial (registered 2015): a planned safety study of an oral form in healthy volunteers. No results have been published.
That adds up to fewer than 30 people across three uncontrolled studies. No placebo-controlled trial has been published, and there has been no completed Phase II trial. In its July 2026 briefing, FDA staff concluded there was a lack of evidence that BPC-157 is effective for the condition it was nominated for, ulcerative colitis.
“Is it healing, or just masking pain?”
This is one of the most common questions on Reddit, and it is a fair one. In animals, studies measured tissue repair directly. In people, the only efficacy data come from patients reporting how they feel, without a comparison group. So there is currently no human evidence showing whether BPC-157 repairs tissue, relieves pain, or neither. Feeling better is not the same as healing, and pain is sometimes a useful warning not to overload an injury.
Doses used in research
There is no established human dose of BPC-157. No dose-finding study has been published, and the handful of human pilot studies used different routes, amounts and schedules without control groups. Amounts circulating online are community practice, not evidence. We don’t publish dosing protocols. If you are considering BPC-157, the dose is a decision for a licensed prescriber.
Side effects and safety concerns
Because controlled human safety data are so limited, the full side-effect profile of BPC-157 is unknown. Effects reported in research and by users include:
- Injection-site pain, redness, swelling or irritation
- Headache
- Nausea or stomach discomfort
- Dizziness
- Fatigue or changes in sleep
- Flushing
- Changes in appetite
In recent Reddit discussions (August to November 2026), users have also described anxiety, low or flat mood, brain fog, old injuries aching again, and in one thread, throat tightness. These are individual reports and can’t show what caused the symptoms, but they are worth knowing about. Investigative reporting by KFF Health News in October 2026 also documented people who said they developed migraines and other lasting symptoms after using BPC-157.
When to get help now
Throat tightness, swelling of the face or tongue, difficulty breathing or a widespread rash can signal a serious allergic reaction. Call 911 or your local emergency number.
Wider concerns raised by the FDA and researchers include:
- Immune reactions: the FDA has flagged possible immunogenicity, meaning the body may react to the peptide or impurities in it.
- Product quality: products sold online as “research use only” are not made to medicine standards. Independent testing has found products with the wrong amount, impurities or contamination.
- Unknown long-term effects: no long-term human safety data exist.
- Blood-vessel growth: researchers have raised questions about what promoting angiogenesis could mean for people with cancer or a history of cancer. This is a theoretical concern, not a demonstrated effect.
- Interactions, pregnancy and breastfeeding: unknown.
The FDA received three adverse-event reports after BPC-157 injections before its July 2026 review, including one of nine days of redness and swelling at the injection site.
Is BPC-157 legal? Regulatory status (November 2026)
United States
- Not FDA approved. BPC-157 has never been approved as a drug.
- September 2023 to April 2026: the FDA placed BPC-157 in “Category 2”, substances it said raised significant safety concerns for compounding.
- July 23, 2026: the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the list of substances licensed pharmacies may compound. FDA staff had recommended against it. The vote was advisory only.
- October 30, 2026: HHS published an interim enforcement-discretion policy. HHS says it does not intend to take action against state-licensed 503A pharmacies, federal facilities or licensed physicians that compound BPC-157 acetate in subcutaneous, intramuscular, oral or topical forms, provided set conditions are met. Those conditions include a patient-specific prescription and a product containing only one listed peptide.
What this means in practice: a US prescriber can now order compounded BPC-157 from a licensed pharmacy without that pharmacy facing federal enforcement, for now. It does not make BPC-157 FDA approved, it is temporary until the FDA finishes rulemaking, and it does not legitimize “research use only” products sold online. The FDA can still decline to add BPC-157 to the permanent list.
Other countries (as of September 2026)
- Australia: unapproved. The TGA names BPC-157 as an example of an unapproved peptide product.
- Canada: unauthorized. Health Canada lists it among unauthorized injectable peptide drugs.
- New Zealand, United Kingdom and European Union: no marketing authorization identified.
Sport
BPC-157 is prohibited at all times under World Anti-Doping Agency rules, in the category for non-approved substances. Athletes subject to testing should not use it.
BPC-157 and TB-500: the “Wolverine stack”
BPC-157 is most often discussed online alongside TB-500, a combination nicknamed the Wolverine stack, on the theory that the two act on repair through different pathways. Other pairings discussed in peptide communities include BPC-157 with GHK-Cu (skin and collagen), with KPV (gut inflammation) and with CJC-1295 and ipamorelin (exercise recovery). None of these combinations has been studied in people. We describe them because people ask, not as a recommendation. Note that the HHS compounding policy only covers products containing a single listed peptide.
Storage and preparation
BPC-157 is usually supplied as a freeze-dried powder that is mixed with bacteriostatic water before use. There is no validated consumer shelf life for BPC-157, either as a powder or once mixed. Community guidance generally describes keeping the powder cool, dry and away from light, and keeping mixed vials refrigerated at 2–8°C (36–46°F) without repeated warming or freezing. Products shipped without cooling are a common worry online, and there is no way to confirm from appearance alone whether a product has degraded.
For the math of mixing, and what to do if a vial looks cloudy, foams or gels, see our reconstitution guide and calculator.
Frequently asked questions
Is BPC-157 FDA approved?
No. BPC-157 has never been approved by the FDA, or by any other major regulator, as a medicine for any condition. The July 2026 advisory committee vote and the October 2026 HHS policy are about pharmacy compounding, not approval.
Is BPC-157 legal in the US now?
As of November 2026, HHS says it does not intend to take enforcement action against state-licensed 503A pharmacies, federal facilities or licensed physicians that compound BPC-157 acetate under set conditions, including a patient-specific prescription. That is an interim enforcement policy while the FDA completes rulemaking. It is not FDA approval, and it does not cover products sold online as research-use-only chemicals.
Does BPC-157 work in humans?
Nobody knows yet. There are more than 100 animal and laboratory studies, but the published human evidence is three small pilot studies with no control groups. No placebo-controlled trial has been published.
What are the side effects of BPC-157?
Reported effects include injection-site redness or swelling, headache, nausea, dizziness, fatigue and changes in mood or sleep. Because controlled human safety data are so limited, the full side-effect profile is unknown. Throat tightness or difficulty breathing can signal a serious allergic reaction and needs emergency care.
Is BPC-157 banned in sport?
Yes. BPC-157 is prohibited for athletes subject to anti-doping rules, under the World Anti-Doping Agency’s category for non-approved substances.
Can BPC-157 be combined with TB-500?
The pairing, often called the Wolverine stack, is widely discussed online, but there is no human research on the combination. The HHS compounding policy also only covers products containing a single listed peptide.
Related: Retatrutide: what it is, trial results, side effects and legal status
Sources
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, HHS, Federal Register, October 30, 2026
- HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides, Holland & Knight, November 4, 2026
- FDA advisory committee backs two controversial peptides, Regulatory Focus (RAPS), July 23, 2026
- HHS draft policy eases enforcement on 6 compounded peptides, AJMC, October 29, 2026
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study, Altern Ther Health Med, 2024
- Lee E, Burgess J. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 2025 (PMID 40131143)
- Vasireddi et al. Systematic review of BPC-157 in orthopaedic sports medicine. HSS Journal, 2025
- PCO-02 Safety and Pharmacokinetics Trial (NCT02637284), ClinicalTrials.gov
- People Say These Peptides Hurt Them, KFF Health News, October 2026
- The Peptide Reference Guide, Volume 1 (Jangie Press, 2026)
- Reddit community discussions, August to November 2026, reviewed to identify common questions only. They were not used as a source of facts.
This article is general educational information and isn’t medical advice. Read our full medical disclaimer.
